StreetInsider.com News Articles

Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference

Tue, 22 Sep 2026 08:00:00 -0400

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend the corporate presentation at https://lythampartners.com/fall2026/

CUPERTINO, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today that Laxminarayan Bhat, PhD., Founder, President and CEO, will present will participate in a webcast presentation at the

Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference

Tue, 22 Sep 2026 08:00:00 -0400

Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference

Tue, 22 Sep 2026 08:00:00 -0400

Reviva to Participate in the Lytham Partners Fall 2026 Investor Conference

Tue, 22 Sep 2026 08:00:00 -0400

Reviva Pharmaceuticals Holdings, Inc. (RVPH) Tops Q2 EPS by 22c

Wed, 12 Aug 2026 17:08:33 -0400

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) reported Q2 EPS of ($0.19), $0.22 better than the analyst estimate of ($0.41).

For earnings history and earnings-related data on Reviva Pharmaceuticals Holdings, Inc. (RVPH) click here.

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:29:00 -0400

- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 -

- FDA feedback on use of new brilaroxazine formulation in the RECOVER-2 trial and NDA expected Q4 2026 -

- Patient enrollment in RECOVER-2 registrational Phase 3 trial expected to initiate in 1H 2027 -

CUPERTINO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (OTCQB: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:29:00 -0400

- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 -

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:29:00 -0400

- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 -

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:29:00 -0400

- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 -

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:29:00 -0400

- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 -

Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Wed, 12 Aug 2026 16:29:00 -0400

- U.S. composition of matter patent application filed seeking accelerated review for a new form of brilaroxazine designed to extend patent life and commercial exclusivity through 2046 -

Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th